Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when HUMA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsHumacyte announces Phase 3 trial results for tissue engineered vessel in female dialysis patients
Filed June 10, 2026 · Period ending June 10, 2026 · ~1 min read
Key Changes
-
high
Company disclosed results from Phase 3 clinical trial (V012) testing its acellular tissue engineered vessel (ATEV) for arteriovenous access in female end-stage renal disease patients requiring hemodialysis—a key regulatory milestone for its lead product.
Item 7.01 view on EDGAR → -
medium
Released new investor presentation to accompany the clinical data announcement, which will be used in upcoming investor calls and conferences to provide additional context on the trial results.
Item 7.01 view on EDGAR →
Summary
Humacyte announced results from its pivotal Phase 3 clinical trial evaluating its tissue engineered vessel product in female hemodialysis patients with end-stage renal disease. This represents a critical regulatory milestone for the company's lead product candidate, as Phase 3 data typically forms the basis for regulatory approval submissions. The specific focus on female patients suggests the company may be pursuing approval in a defined patient population.
For retail investors, this disclosure matters because successful Phase 3 results could accelerate the path to commercialization and revenue generation for Humacyte's core technology platform. The company simultaneously released an investor presentation to provide additional detail on the findings. Watch for follow-up announcements regarding regulatory submissions to the FDA or other health authorities, as well as any commentary on the commercial opportunity size and potential launch timelines.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On June 10, 2026, the Company made available an investor presentation (the “Investor Presentation”), which the Company expects to use in connection with investor calls and/or conferences.
The company released a new investor presentation that will be used for investor communications. This typically accompanies significant corporate updates or milestones and provides additional context for investors.
Event · Item 9.01 — Financial Statements and Exhibits
Humacyte filed an 8-K attaching a press release and investor presentation dated June 10, 2026, with no material event details disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Exhibit | Number | Description | 99.1 | Press release, dated June 10, 2026. | 99.2 Humacyte, Inc. Investor Presentation June 2026.
The company filed two exhibits: a press release and an investor presentation both dated June 10, 2026. The 8-K body does not disclose the content or subject matter of these documents, so the nature and materiality of any announcements cannot be determined from this filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify